首页> 外文期刊>Journal of drugs in dermatology: JDD >Not All Topical Corticosteroids are Created Equal! Optimizing Therapeutic Outcomes Through Better Understanding of Vehicle Formulations, Compound Selection, and Methods of Application
【24h】

Not All Topical Corticosteroids are Created Equal! Optimizing Therapeutic Outcomes Through Better Understanding of Vehicle Formulations, Compound Selection, and Methods of Application

机译:并非所有的局部皮质类固醇激素都是一样的!通过更好地理解媒介物配方,化合物选择和应用方法来优化治疗效果

获取原文
获取原文并翻译 | 示例
           

摘要

Since the first successful topical glucocorticosteroid, compound F, was applied to human skin to treat eczematous dermatitis approximately 60 years ago, several advances have been made in the development of topical corticosteroid (TC) compounds and vehicle formulations. (1-3)The ability to apply a TC and improve skin disease revolutionized dermatologic therapy and has proven to be one of the biggest advances in the history of dermatology. The potency of a TC and their vehicle formulation can vary among brand and generic TC compounds, which can sometimes confound the clinical situation as one brand or generic formulation of a givenTC may be well tolerated while another generic formulation induces skin irritation or allergenicity in a patient who previously encountered no difficulties. J Drugs Dermatol. 2012;11(suppl 12) s5-s8.
机译:自大约60年前将第一种成功的局部用糖皮质激素类化合物F应用于人皮肤以治疗湿疹性皮炎以来,局部用皮质类固醇(TC)化合物和赋形剂的开发取得了一些进展。 (1-3)应用TC和改善皮肤疾病的能力彻底改变了皮肤病学疗法,并被证明是皮肤病学史上最大的进步之一。 TC的效力及其媒介制剂在品牌和非专利TC化合物之间可能会有所不同,这有时会混淆临床情况,因为给定TC的一个品牌或非专利制剂可能具有良好的耐受性,而另一种非专利制剂会引起患者的皮肤刺激性或过敏性以前没有遇到困难的人。 J Drugs Dermatol。 2012; 11(suppl 12)s5-s8。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号